The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Janux Therapeutics Inc shares valued at $106,745 were sold by Meyer Andrew Hollman on May 01 ’25. At $32.03 per share, Meyer Andrew Hollman sold 3,333 shares. The insider’s holdings dropped to 82,139 shares worth approximately $2.04 million following the completion of this transaction.
Also, ANDREW MEYER purchased 3,333 shares, netting a total of over 110,656 in proceeds.
Before that, Meyer Andrew Hollman had sold 3,334 shares from its account. In a trade valued at $100,020, the Chief Business Officer traded Janux Therapeutics Inc shares for $30.00 each. Upon closing the transaction, the insider’s holdings decreased to 3,334 shares, worth approximately $2.04 million.
As published in their initiating research note from Piper Sandler on August 19, 2025, Janux Therapeutics Inc [JANX] has been an Overweight and the price target has been revised to $42. Analysts at Raymond James started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid July. As of December 03, 2024, H.C. Wainwright has reiterated its “Buy” rating for JANX. Earlier on December 03, 2024, BTIG Research resumed its rating. Their recommendation was “a Buy” for JANX stock.
Analyzing JANX Stock Performance
On last trading session, Janux Therapeutics Inc [NASDAQ: JANX] rose 0.69% to $24.87. The stock’s lowest price that day was $24.211, but it reached a high of $25.13 in the same session. During the last five days, there has been a drop of approximately -0.36%. Over the course of the year, Janux Therapeutics Inc shares have dropped approximately -39.81%. Shares of the company reached a 52-week high of $61.59 on 01/07/25 and a 52-week low of $21.97 on 08/11/25.
Support And Resistance Levels for Janux Therapeutics Inc (JANX)
According to the 24-hour chart, there is a support level at 24.34, which, if violated, would cause prices to drop to 23.81. In the upper region, resistance lies at 25.27. The next price resistance is at 25.67. RSI (Relative Strength Index) is 51.14 on the 14-day chart, showing neutral technical sentiment.
Is Janux Therapeutics Inc subject to short interest?
Stocks of Janux Therapeutics Inc saw a sharp steep in short interest on 2025-07-31 dropping by -1.53 million shares to 8.73 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 10.26 million shares. A decline of -17.49% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.83 of the overall float, the days-to-cover ratio (short ratio) decline to 10.83.
Which companies own the most shares of Janux Therapeutics Inc (JANX)?
In terms of Janux Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 65 in the next 12 months, up nearly 163.16% from the previous closing price of $24.7. Analysts anticipate Janux Therapeutics Inc stock to reach 76 by 2025, with the lowest price target being 41. In spite of this, 3 analysts ranked Janux Therapeutics Inc stock as Buy at the end of 2025. On November 22, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and initiated coverage with a $79.
